TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8611872
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative intravenous fluids
Study: 2502417
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g cholestyramine
Study: 6214264
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g cholestyramine
Study: 6214264
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g cholestyramine
Study: 6214264
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of cholestyramine
Study: 31743169
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 µg/kg (D 1)
Study: 31743169
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg/kg (D 0.5)
Study: 31743169
Drug: Dexmedetomidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.25 µg/kg (D 0.25)
Study: 27852708
Drug: Aveeno lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aveeno lotion
Study: 27852708
Drug: Diprobase cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprobase cream
Study: 27852708
Drug: Doublebase gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublebase gel
Study: 27852708
Drug: Hydromol ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromol ointment
Study: 17409317
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (Losartan and Placebo)
Study: 9726683
Drug: Ceftibuten (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (9 mg/kg q.d. for 14 days)
Study: 9726683
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (nasal saline drops allowed)
Study: 8039152
Drug: Sequential tamoxifen/megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential tamoxifen/megestrol for 2 years
Study: 8039152
Drug: High‐dose chemotherapy+autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose chemotherapy+autologous bone marrow transplantation
Study: 8039152
Drug: CMF- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF- or FEC-chemotherapy plus APD (pamidronate)
Study: 30793734
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg with P2Y12 inhibitor
Study: 30793734
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg with P2Y12 inhibitor
Study: 27655276
Drug: Buccal oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal oxygenation via a modified 3.5‐mm Ring‐Adair‐Elwyn (RAE) tube
Study: 19959920
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored intervention program consisting of physical and daily activities led by physiotherapists and occupational therapists for three months
Study: 17303627
Drug: Best antiarrhythmic
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best antiarrhythmic drug therapy
Study: 4039870
Drug: Acellular preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular preparation
Study: 29454724
Drug: Normal glucose
Normalized name: Normal Glucose Control Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal glucose metabolism
Study: 29454724
Drug: Normal glucose
Normalized name: Normal Glucose Control Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal glucose metabolism (glycosylated hemoglobin and fasting plasma glucose)
Study: 29454724
Drug: Abnormal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal glucose metabolism (both diagnostic approaches)
Study: 26926775
Drug: Rifaximin alone
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin alone (550 mg twice daily for 3 months)
Study: 26926775
Drug: Rifaximin in
Normalized name: Product containing rifaximin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin in combination with lactulose (30-60 ml daily for 3 months)
Study: 21887685
Drug: Bortezomib 1
Normalized name: bortezomib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1 mg/m2 × 3 doses (Group 2)
Study: 21887685
Drug: Bortezomib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.5 mg/m2 × 3 doses (Group 3)
Study: 19091394
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment alone (3 months of total androgen blockade followed by continuous endocrine treatment using flutamide)
Study: 19286422
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment plus radiotherapy
Study: 19286422
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment alone
Study: 8917264
Drug: 17‐beta‐estradiol patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17‐beta‐estradiol patches (100 micrograms/24 h)
Study: 3885664
Drug: Single-dose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (1 g) intravenous metronidazole prophylaxis
Study: 3885664
Drug: No prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylaxis and doxycycline therapy in case of perforation
Study: 26816605
Drug: Subject-driven titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject-driven titration of BIAsp 30 BID
Study: 26816605
Drug: Investigator-driven titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-driven titration of BIAsp 30 BID
Study: 25337749
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 4 months of daily isoniazid and rifampicin)
Study: 25337749
Drug: 6-month regimen
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month regimen (daily moxifloxacin for 2 months followed by weekly moxifloxacin and 1200 mg rifapentine for 4 months)
Study: 25337749
Drug: 4-month regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month regimen (daily moxifloxacin for 2 months followed by moxifloxacin and 900 mg rifapentine twice weekly for 2 months)
Study: 17426742
Drug: Muesli with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muesli with 4 g beta-glucans
Study: 17426742
Drug: Muesli with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muesli with 3 g beta-glucans
Study: 14607575
Drug: Oral sibutramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sibutramine (10 mg/day)
Study: 14607575
Drug: Oral EE‐CPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral EE‐CPA (35 microg‐2 mg/day)
Study: 14607575
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EE‐CPA plus sibutramine
Study: 1633069
Drug: Solid micellar
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid micellar solution
Study: 1633069
Drug: Faster releasing
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster releasing microemulsion formulation
Study: 1633069
Drug: Standard soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard soft gelatine preparation
Study: 27185903
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine pressurized metered dose inhaler (pMDI) plus active nicotine patch
Study: 27185903
Drug: Placebo pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pMDI plus active nicotine patch
Study: 22919348
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) with conventional medical treatment, 10 sessions within 3-5 days after stroke onset.
Study: 22919348
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment without HBOT.
Study: 9464714
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and conjugated equine estrogens 0.625 mg daily (Group C)
Study: 9464714
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and conjugated equine estrogens 1.25 mg daily (Group D)
Study: 9464714
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + placebos for progestin and estrogen (Group A)
Study: 9464714
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and placebo for estrogen (Group B)
Study: 9464714
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg daily (Group C)
Study: 9464714
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg daily (Group D)
Study: 2773686
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen administered continuously via programmable pump (90 to 150 micrograms per day)
Study: 2773686
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine single injection
Study: 2773686
Drug: Baclofen bolus
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen bolus injection (30 to 60 micrograms)
Study: 26735264
Drug: Oral α-lipoic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral α-lipoic acid (ALA), betamethasone injection, and NB-UVB
Study: 26735264
Drug: Placebo, betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, betamethasone injection, and NB-UVB
Study: 25046949
Drug: Yiqi Huaju
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Huaju Recipe (YHR) combined with routine therapy
Study: 25046949
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy + placebo (Control)
Study: 23520670
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol 20 mg
Study: 23520670
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol 40 mg
Study: 11413842
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LAS) 1 g twice daily on Day 1 and 1 g three times daily on Day 2
Study: 11413842
Drug: Paracetamol (PAR)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (PAR) 1 g twice daily on Day 1 and 1 g three times daily on Day 2
Study: 7946588
Drug: Low-dose gamma-interferon
Normalized name: gamma-interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose gamma-interferon (gamma IFN) at doses of 100, 200, or 400 micrograms, administered daily or weekly for a minimum of 3 months after a 2-week cycle.
Study: 7946588
Drug: Comparison to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison to other low-dose gamma IFN trials.
Study: 3680556
Drug: Nimesulide 100
Normalized name: nimesulide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100 mg oral doses
Study: 3680556
Drug: Nimesulide 200
Normalized name: nimesulide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200 mg/d PO
Study: 20961633
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment Arm (STA)
Study: 20565333
Drug: Memantine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine at 20 mg/day
Study: 17689932
Drug: Adalimumab (TNFalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (TNFalpha inhibitor)
Study: 8848890
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 with atropine 10 micrograms kg‐1
Study: 1982774
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg propiomazine
Study: 19049993
Drug: Immediate administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate administration of misoprostol after mifepristone (600 microg vaginally)
Study: 19049993
Drug: 36-38 h
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36-38 h administration of misoprostol after mifepristone (600 microg vaginally)
Study: 19049993
Drug: 36-38 h
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36-38 h administration of misoprostol
Study: 19049993
Drug: Immediate administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate administration of misoprostol
Study: 11231032
Drug: L-threonine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine with pyridoxal 5-phosphate
Study: 7727908
Drug: Opiate sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate sedation plus low dose midazolam (1 mg/hour)
Study: 30985449
Drug: Restrictive IV
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive IV fluid resuscitation strategy (≤ 60 mL/kg of IV fluid)
Study: 28453978
Drug: Intra-nasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-nasal administration of Oxytocin
Study: 25761587
Drug: gonadotrophin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: gonadotrophin‐releasing hormone analogue (GnRH‐a) monthly for 6 months
Study: 25761587
Drug: gonadotrophin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: gonadotrophin‐releasing hormone analogue (GnRH‐a)
Study: 8044013
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine group (CMG) treated with Tongjingbao and Angelicae Complex Injection
Study: 8044013
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (WMG) treated with Gentamycin, Dexamethasone, Chymotrypsin
Study: 3255916
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A of tripotassium dicitrato bismuthate (TDB)
Study: 3255916
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B of tripotassium dicitrato bismuthate (TDB)
Study: 28633477
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (high doses)
Study: 28633477
Drug: Diuretics withdrawal
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics withdrawal
Study: 28633477
Drug: Diuretics (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (general use)
Study: 28633477
Drug: Diuretics decrease
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics decrease (from a small randomized study)
Study: 21401865
Drug: rPSGL-Ig (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPSGL-Ig (1 mg/kg systemic dose with pretransplant allograft ex vivo treatment)
Study: 12948258
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ACTH (1 microg) test
Study: 12948258
Drug: Both low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both low dose and standard dose ACTH tests
Study: 10890484
Drug: Histamine2-receptor antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Histamine2-receptor antagonists or antacids
Study: 10170453
Drug: SSRIs (fluoxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (fluoxetine, fluvoxamine, sertraline, paroxetine)
Study: 2947462
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide metered-dose inhaler (40 micrograms four times a day)
Study: 2947462
Drug: Metaproterenol metered-dose
Normalized name: metaproterenol sulfate Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol metered-dose inhaler (1,500 micrograms four times a day)
Study: 30462260
Drug: Rifamycin SV‐MMX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifamycin SV‐MMX® 400 mg twice daily
Study: 21094019
Drug: Integrated interpersonal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated interpersonal cognitive‐behavioral group treatment (ICBT)
Study: 16645969
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg/day
Study: 12553635
Drug: Pure lanolin
Normalized name: CVS Pure Lanolin 100% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure lanolin cream used twice daily for 4 weeks
Study: 12553635
Drug: Ammonium lactate
Normalized name: Ammonium Lactate
DrugBank: Ammonium lactate (DB06768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ammonium lactate 12% cream used twice daily for 4 weeks
Study: 8840633
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) 240 mg twice daily (Group 1)
Study: 8840633
Drug: Sucralfate 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2.0 g twice daily (Group 3)
Study: 1458144
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 mg/day); 14% required additional diuretics.
Study: 1458144
Drug: Enalapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (40 mg/day); 76% required diuretics.
Study: 29982727
Drug: GEN-003 30
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 30 µg antigen/25 µg adjuvant
Study: 29982727
Drug: GEN-003 30
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 30 µg antigen/50 µg adjuvant
Study: 29982727
Drug: GEN-003 30
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 30 µg antigen/75 µg adjuvant
Study: 29982727
Drug: GEN-003 60
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 60 µg antigen/25 µg adjuvant
Study: 29982727
Drug: GEN-003 60
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 60 µg antigen/50 µg adjuvant
Study: 29982727
Drug: GEN-003 60
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 60 µg antigen/75 µg adjuvant
Study: 29982727
Drug: GEN-003 60
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 60 µg antigen plus 50 or 75 µg adjuvant
Study: 26803595
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1000 mg DHA; 200 mg EPA)
Study: 26803595
Drug: EPA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA supplementation (1000 mg EPA; 200 mg DHA)
Study: 25276669
Drug: Chart presenting
Normalized name: Stachybotrys chartarum
DrugBank: Stachybotrys chartarum (DB10847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chart presenting pregnancy risk with combined pills
Study: 16258100
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Treatment-Fatigue scores
Study: 16258100
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Treatment-Endocrine Symptoms scores
Study: 12114419
Drug: ISIS 3521
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 3521 (2 mg/kg/day as continuous i.v. infusion for 21 of 28 days)
Study: 12114419
Drug: ISIS 5132
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 5132 (2 mg/kg/day as continuous i.v. infusion for 21 of 28 days)
Study: 8673001
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (30 mg/day) for up to 2 years
Study: 2181856
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer Polycose (100 or 150 g daily for 6 months)
Study: 7194063
Drug: etofylline clofibrate
Normalized name: etofylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: etofylline clofibrate (Duolip) treatment
Study: 30241990
Drug: Omega-3 (EPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (EPA 740 mg and DHA 400 mg daily)
Study: 26886460
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment (thoracolumbosacral orthosis, at least 18 h/d)
Study: 19526752
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (Xinyue Capsule and compound Tanshinon Tablet)